June 10, 2016 by CDR Blog
Federal Trade Commission, FTC, Rite Aid, Walgreens Boots Alliance, WBA-Rite Aid merger
CDR Blog
Shares of Walgreens Boots Alliance and Rite Aid edged up on Friday following a news report that the Federal Trade Commission is looking more favorably at the companies’ merger deal. The New York Post reported late Thursday that there are “growing signs” the FTC will give the green light to WBA’s $17.2 billion deal to
January 4, 2016 by Geoff Walden and Chain Drug Review
Federal Trade Commission, John Standley, Rite Aid, Stefano Pessina, Walgreens Boots Alliance
2016, Issue 01-04-2016, Issues, News
CAMP HILL, Pa. — Rite Aid Corp. stockholders will vote next month on the company’s merger with Walgreens Boots Alliance (WBA). Rite Aid has scheduled a February 4 special stockholders meeting for the balloting. Stockholders as of the close of business on December 18 will be eligible to vote. Rite Aid and WBA also announced
December 11, 2015 by Chain Drug Review
Federal Trade Commission, Rite Aid, Walgreens Boots Alliance, WBA-Rite Aid
Business, Featured Articles, Leading Headlines, Retail News
DEERFIELD, Ill., and CAMP HILL, Pa. —The Federal Trade Commission has requested additional information from Walgreens Boots Alliance (WBA) Inc. and Rite Aid Corp. regarding WBA’s proposed acquisition of Rite Aid. WBA and Rite Aid said Friday that the second request for information, made under the notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act, extends
November 9, 2015 by Geoff Walden and Chain Drug Review
Adam Fein, Amy Klobuchar, B. Douglas Hoey, Drug Channels Institute, Federal Trade Commission, Mike Lee, National Community Pharmacists Association, Rite Aid, Walgreens Boots Alliance, Walgreens-Rite Aid merger
2015, Issue 11-09-2015, Issues, News
DEERFIELD, Ill. — Walgreens Boots Alliance may have to divest up to 400 of the Rite Aid stores it is acquiring to satisfy antitrust regulations, analysts said. WBA is not publicly speculating on how many units it will have to shutter, said chief executive officer Stefano Pessina. “We have analyzed things very carefully,” he said
October 29, 2015 by Chain Drug Review
biological products, biosimilar, biosimilar naming convention, Federal Trade Commission, Food and Drug Administration
Leading Headlines, Pharmacy, Supplier News
WASHINGTON — The staff of the Federal Trade Commission has submitted comment for the Food and Drug Administration’s draft guidance on nonproprietary names for biological products. The FTC said Wednesday that its staff comment expressed concern that the FDA draft guidance on biosimilar naming may hinder competition and, as a result, recommended that the agency